Prevalence of Fabry Disease in Patients With Cryptogenic Strokes: A Systematic Review
Affiliations
Affiliations
- Neurology, Larkin Community Hospital, Miami, USA.
- Neurology, Lokmanya Tilak Municipal Medical College, Mumbai, IND.
- General Practice, Drexel University College of Medicine, Philadelphia, USA.
- Neurology, Universidad San Francisco de Quito, Quito, ECU.
- Medicine and Surgery, University of Parma, Parma, ITA.
- Progressive Care Unit, Mercy Medical Center, Baltimore, USA.
- Medicine, Universidad San Francisco de Quito, Quito, ECU.
- Public Health, University of California Berkeley, Berkeley, USA.
- Medicine, Universidad Internacional del Ecuador, Quito, ECU.
- Emergency Medicine, Amiri Hospital, Kuwait City, KWT.
- Internal Medicine, Palisades Medical Center, North Bergen, USA.
Abstract
Fabry disease (FD) is an X-linked disorder involving multiple organs. Stroke is a serious and frequent complication of FD. Cryptogenic stroke is a common presentation of FD, especially in the young population. The etiology of cryptogenic stroke is highly variable and difficult to assess, frequently leaving patients without a primary diagnosis. We conducted a systematic review to investigate the pooled prevalence of FD among patients with cryptogenic stroke, or patients with FD in whom a stroke was the presenting condition. English-language studies involving humans published in the last 20 years were included in this systematic review. FD was more common in male patients and tended to present at an earlier age. The frequency of hemorrhagic and ischemic strokes in this population was similar to that in the general population. There was a high rate of stroke recurrence in the study sample, even among patients undergoing enzyme replacement therapy. We conclude that screening for FD in patients with cryptogenic stroke is low yield and not cost-effective. However, it may be worthwhile to screen for FD among patients with recurrent strokes.
Keywords: alpha-galactosidase; cryptogenic stroke; fabry disease; ischemic stroke; stroke.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
Sarikaya H, Yilmaz M, Michael N, Miserez AR, Steinmann B, Baumgartner RW.Eur J Neurol. 2012 Nov;19(11):1421-6. doi: 10.1111/j.1468-1331.2012.03737.x. Epub 2012 Jun 11.PMID: 22680335
Romani I, Borsini W, Nencini P, Morrone A, Ferri L, Frusconi S, Donadio VA, Liguori R, Donati MA, Falconi S, Pracucci G, Inzitari D.J Stroke Cerebrovasc Dis. 2015 Nov;24(11):2588-95. doi: 10.1016/j.jstrokecerebrovasdis.2015.07.012. Epub 2015 Aug 19.PMID: 26298600
The Frequency of Fabry Disease among Young Cryptogenic Stroke Patients in the City of Sakarya.
Gündoğdu AA, Kotan D, Alemdar M.J Stroke Cerebrovasc Dis. 2017 Jun;26(6):1334-1340. doi: 10.1016/j.jstrokecerebrovasdis.2017.02.004. Epub 2017 Mar 7.PMID: 28283366
Neurological complications of Anderson-Fabry disease.
Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Arnao V, Licata G, Pinto A.Curr Pharm Des. 2013;19(33):6014-30. doi: 10.2174/13816128113199990387.PMID: 23448452 Review.
Nill M, Müller MJ, Beck M, Stoeter P, Fellgiebel A.Fortschr Neurol Psychiatr. 2006 Dec;74(12):687-95. doi: 10.1055/s-2006-932190.PMID: 17167727 Review. German.
References
-
- The frequency of Fabry disease among young cryptogenic stroke patients in the city of Sakarya. Gündoğdu AA, Kotan D, Alemdar M. J Stroke Cerebrovasc Dis. 2017;26:1334–1340. - PubMed
-
- Prevalence of Fabry disease in young patients with cryptogenic ischemic stroke. Dubuc V, Moore DF, Gioia LC, Saposnik G, Selchen D, Lanthier S. J Stroke Cerebrovasc Dis. 2013;22:1288–1292. - PubMed
-
- Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Moore DF, Ye F, Schiffmann R, Butman JA. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149001/ AJNR Am J Neuroradiol. 2003;24:1096–1101. - PMC - PubMed
-
- Fabry disease: recognition, diagnosis, and treatment of neurological features. Ranieri M, Bedini G, Parati EA, Bersano A. Curr Treat Options Neurol. 2016;18:33. - PubMed
-
- Stroke and Fabry disease. Viana-Baptista M. J Neurol. 2012;259:1019–1028. - PubMed
-
- MOOSE reporting guidelines for meta-analyses of observational studies. Brooke BS, Schwartz TA, Pawlik TM. https://jamanetwork.com/journals/jamasurgery/article-abstract/2778476. JAMA Surg. 2021;156:787–788. - PubMed
-
- Prevalence of Fabry disease and outcomes in young Canadian patients with cryptogenic ischemic cerebrovascular events. Lanthier S, Saposnik G, Lebovic G, Pope K, Selchen D, Moore DF. Stroke. 2017;48:1766–1772. - PubMed
-
- Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Rolfs A, Böttcher T, Zschiesche M, et al. Lancet. 2005;366:1794–1796. - PubMed
-
- Screening for Fabry disease in Japanese patients with young-onset stroke by measuring α-galactosidase A and globotriaosylsphingosine. Kinoshita N, Hosomi N, Matsushima H, et al. J Stroke Cerebrovasc Dis. 2018;27:3563–3569. - PubMed
-
- Middelheim Fabry Study (MiFaS): a retrospective Belgian study on the prevalence of Fabry disease in young patients with cryptogenic stroke. Brouns R, Sheorajpanday R, Braxel E, et al. Clin Neurol Neurosurg. 2007;109:479–484. - PubMed
-
- Zurich Fabry study - prevalence of Fabry disease in young patients with first cryptogenic ischaemic stroke or TIA. Sarikaya H, Yilmaz M, Michael N, Miserez AR, Steinmann B, Baumgartner RW. Eur J Neurol. 2012;19:1421–1426. - PubMed
-
- Prevalence of Fabry disease in young patients with stroke in Argentina. Reisin RC, Mazziotti J, Cejas LL, et al. J Stroke Cerebrovasc Dis. 2018;27:575–582. - PubMed
-
- Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. Hilz MJ, Kolodny EH, Brys M, Stemper B, Haendl T, Marthol H. J Neurol. 2004;251:564–570. - PubMed
-
- Vasculopathy in patients with Fabry disease: current controversies and research directions. Rombach SM, Twickler TB, Aerts JM, Linthorst GE, Wijburg FA, Hollak CE. Mol Genet Metab. 2010;99:99–108. - PubMed
-
- Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Sims K, Politei J, Banikazemi M, Lee P. Stroke. 2009;40:788–794. - PubMed
-
- Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Rolfs A, Fazekas F, Grittner U, et al. Stroke. 2013;44:340–349. - PubMed
-
- Dietary magnesium intake and risk of cardiovascular disease among women. Song Y, Manson JE, Cook NR, Albert CM, Buring JE, Liu S. Am J Cardiol. 2005;96:1135–1141. - PubMed
-
- Fabry's disease and stroke: effectiveness of enzyme replacement therapy (ERT) in stroke prevention, a review with meta-analysis. Sheng S, Wu L, Nalleballe K, et al. J Clin Neurosci. 2019;65:83–86. - PubMed